NCT02834013: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

NCT02834013
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Must have metaplastic breast cancer or cancer that begins in cells that have changed into another cell type; Metaplastic breast cancer is a rare malignancy characterized by the histologic presence of two or more cellular types, commonly a mixture of epithelial and mesenchymal components
Exclusions: Untreated, unstable, and/or symptomatic brain metastases- see trial for details
https://clinicaltrials.gov/show/NCT02834013

Comments are closed.

Up ↑